Eric Sbar

2.0k total citations · 2 hit papers
29 papers, 1.5k citations indexed

About

Eric Sbar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Eric Sbar has authored 29 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Eric Sbar's work include Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (13 papers) and Bladder and Urothelial Cancer Treatments (7 papers). Eric Sbar is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Colorectal Cancer Treatments and Studies (13 papers) and Bladder and Urothelial Cancer Treatments (7 papers). Eric Sbar collaborates with scholars based in United States, Japan and China. Eric Sbar's co-authors include Tony Mok, Tao Wang, Yi‐Long Wu, Kazuhiko Nakagawa, Maria Rita Migliorino, Rafael Rosell, Xiangdong Zhou, Ki Hyeong Lee, Seiji Niho and Adam Płużański and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Eric Sbar

27 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

2017 854 citations Yi‐Long Wu, Ying Cheng et al. The Lancet Oncology profile →
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations

2018 331 citations Tony Mok, Ying Cheng et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Sbar United States	10	1.2k	1.1k	419	239	116	29	1.5k
Xiuyu Julie Cong United States	13	1.3k 1.1×	1.2k 1.2×	563 1.3×	189 0.8×	112 1.0×	19	1.7k
Adam Płużański Poland	15	1.7k 1.4×	1.6k 1.5×	473 1.1×	319 1.3×	102 0.9×	56	2.1k
Jian Hua Shi China	5	1.6k 1.3×	1.3k 1.3×	462 1.1×	305 1.3×	62 0.5×	6	1.7k
Akito Hata Japan	25	1.4k 1.2×	1.1k 1.0×	320 0.8×	325 1.4×	111 1.0×	117	1.7k
Eng-Huat Tan Singapore	12	901 0.8×	857 0.8×	393 0.9×	155 0.6×	192 1.7×	12	1.3k
Masaki Shimoji Japan	15	775 0.6×	676 0.6×	434 1.0×	204 0.9×	89 0.8×	38	1.1k
Vladimir Vladimirov United States	12	677 0.6×	1.3k 1.2×	235 0.6×	300 1.3×	84 0.7×	25	1.6k
Erzsébet Juhász Hungary	15	1.1k 0.9×	1.2k 1.1×	568 1.4×	235 1.0×	71 0.6×	28	1.7k
J. A. Engelman United States	12	1.0k 0.9×	834 0.8×	511 1.2×	257 1.1×	47 0.4×	24	1.3k
Aleksandra Markovets United States	16	1.1k 0.9×	834 0.8×	573 1.4×	392 1.6×	73 0.6×	39	1.4k

Countries citing papers authored by Eric Sbar

Since Specialization

Citations

This map shows the geographic impact of Eric Sbar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Sbar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Sbar more than expected).

Fields of papers citing papers by Eric Sbar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Sbar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Sbar. The network helps show where Eric Sbar may publish in the future.

Co-authorship network of co-authors of Eric Sbar

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Sbar. A scholar is included among the top collaborators of Eric Sbar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Sbar. Eric Sbar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Solomon, Benjamin, Bo Gao, Vivek Subbiah, et al.. (2023). Abstract CT033: Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors. Cancer Research. 83(8_Supplement). CT033–CT033. 8 indexed citations

Schram, Alison M., Vivek Subbiah, Ryan J. Sullivan, et al.. (2023). Abstract CT031: A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors. Cancer Research. 83(8_Supplement). CT031–CT031. 9 indexed citations

Zer, Alona, Julia Dudnik, Sivan Shamai, et al.. (2021). 1331P Open-label phase I/II study evaluating the tolerability and anti-tumor activity of selinexor (SEL) and docetaxel (DTX) in non-small cell lung cancer (NSCLC). Annals of Oncology. 32. S1019–S1019. 1 indexed citations

Galsky, Matthew D., Christopher Hoimes, Andrea Necchi, et al.. (2021). Perioperative Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncology. 17(24). 3137–3150. 38 indexed citations

Galsky, Matt D., Andrea Necchi, Neal D. Shore, et al.. (2021). KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 39(6_suppl). TPS507–TPS507. 18 indexed citations

Galsky, Matt D., Andrea Necchi, Neal D. Shore, et al.. (2020). Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905.. Journal of Clinical Oncology. 38(6_suppl). TPS593–TPS593. 2 indexed citations

Williams, Stephen B., Lauren E. Howard, Zachary Klaassen, et al.. (2020). Long-term outcomes among BCG-treated high-risk non-muscle invasive bladder cancer patients in an equal access setting.. Journal of Clinical Oncology. 38(15_suppl). e17031–e17031.

Wit, Ronald de, Girish S. Kulkarni, Edward Uchio, et al.. (2019). Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). Annals of Oncology. 30. v364–v365. 3 indexed citations

Mok, Tony, Ying Cheng, Xiangdong Zhou, et al.. (2018). Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of Clinical Oncology. 36(22). 2244–2250. 331 indexed citations breakdown →

10.

Mok, Tony, Kazuhiko Nakagawa, Rafael Rosell, et al.. (2018). MA26.11 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC. Journal of Thoracic Oncology. 13(10). S454–S454. 5 indexed citations

11.

Wu, Yi‐Long, Ying Cheng, Xiangdong Zhou, et al.. (2017). Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet Oncology. 18(11). 1454–1466. 854 indexed citations breakdown →

12.

Mok, Tony, Ying Cheng, Xiangdong Zhou, et al.. (2017). Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.. Journal of Clinical Oncology. 35(18_suppl). LBA9007–LBA9007. 26 indexed citations

13.

Kim, Dong‐Wan, Edward B. Garon, Aminah Jatoi, et al.. (2017). Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer. 106. 76–82. 12 indexed citations

14.

Nakagawa, Kazuhiko, Terufumi Kato, Toshiaki Takahashi, et al.. (2017). P3.01-072 Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050). Journal of Thoracic Oncology. 12(11). S2229–S2230. 2 indexed citations

15.

Yu, Helena A., Myung‐Ju Ahn, Byoung Chul Cho, et al.. (2017). Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. Lung Cancer. 112. 195–199. 8 indexed citations

16.

Ramalingam, Sundar, Kenneth J. O’Byrne, Michael Boyer, et al.. (2016). Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Annals of Oncology. 27(3). 423–429. 48 indexed citations

17.

Lacouture, Mario E., Dorothy Keefe, Stephen T. Sonis, et al.. (2016). A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Annals of Oncology. 27(9). 1712–1718. 49 indexed citations

18.

Chow, Laura Q.M., Grace K. Dy, Garth Nicholas, et al.. (2013). A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies. Cancer Chemotherapy and Pharmacology. 71(5). 1273–1285. 2 indexed citations

19.

Gettinger, Scott, Naiyer A. Rizvi, Frances A. Shepherd, et al.. (2012). A phase I study of BMS-936558 in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, or carboplatin/paclitaxel in patients with treatment-naive, stage IIIB/IV non-small-cell lung cancer.. Journal of Clinical Oncology. 30(15_suppl). TPS2615–TPS2615. 2 indexed citations

20.

Sbar, Eric, et al.. (2002). Phase I Study of Sequential Administration of Topotecan and 5-Fluorouracil in Patients with Advanced Malignancies. Cancer Investigation. 20(5-6). 644–650. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact